Muscarinic Receptor Antagonists as a Therapy for Diabetic Neuropathy
Phase of Trial: Phase III
Latest Information Update: 25 May 2018
At a glance
- Drugs Oxybutynin (Primary)
- Indications Diabetic neuropathies
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 15 May 2018 Status changed from recruiting to completed.
- 25 Jul 2017 Planned End Date changed from 1 Jan 2018 to 1 Dec 2018.